Neurocrine Biosciences, Inc. (0K6R.L)
USD 138.27
(1.59%)
USD 138.27
(1.59%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 177.3 Million USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 99.6 Million USD | 125.62% |
| 2020 | -388.7 Million USD | -201.43% |
| 2019 | 383.22 Million USD | 55.29% |
| 2018 | 246.78 Million USD | 114.77% |
| 2017 | 114.9 Million USD | 238.0% |
| 2016 | -83.26 Million USD | -12.23% |
| 2015 | -74.19 Million USD | -139.23% |
| 2014 | -31.01 Million USD | 30.76% |
| 2013 | -44.78 Million USD | 29.75% |
| 2012 | -63.75 Million USD | -27.24% |
| 2011 | -50.1 Million USD | 7.3% |
| 2010 | -54.05 Million USD | -109.51% |
| 2009 | -25.79 Million USD | 62.32% |
| 2008 | -68.46 Million USD | 30.26% |
| 2007 | -98.17 Million USD | -259.1% |
| 2006 | -27.34 Million USD | -389.13% |
| 2005 | 9.45 Million USD | 85.45% |
| 2004 | 5.09 Million USD | 107.35% |
| 2003 | -69.42 Million USD | -90.83% |
| 2002 | -36.37 Million USD | 77.01% |
| 2001 | -158.2 Million USD | -819.35% |
| 2000 | -17.2 Million USD | 5.45% |
| 1999 | -18.2 Million USD | -109.2% |
| 1998 | -8.7 Million USD | 38.73% |
| 1997 | -14.2 Million USD | -46.39% |
| 1996 | -9.7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 150.6 Million USD | -15.06% |
| 2024 Q2 | 151.9 Million USD | 0.86% |
| 2024 Q3 | -97.7 Million USD | -164.32% |
| 2023 Q3 | -37.9 Million USD | -138.44% |
| 2023 Q1 | 350.3 Million USD | 0.0% |
| 2023 Q4 | 177.3 Million USD | 567.81% |
| 2023 Q2 | 98.6 Million USD | -71.85% |
| 2023 FY | 177.3 Million USD | 0.0% |
| 2022 Q2 | 105.3 Million USD | -49.86% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q1 | 210 Million USD | 110.84% |
| 2022 FY | - USD | -100.0% |
| 2022 Q3 | 53.6 Million USD | -49.1% |
| 2021 FY | 99.6 Million USD | 125.62% |
| 2021 Q1 | 76.9 Million USD | 119.78% |
| 2021 Q2 | 67.3 Million USD | -12.48% |
| 2021 Q3 | 126 Million USD | 87.22% |
| 2021 Q4 | 99.6 Million USD | -20.95% |
| 2020 Q4 | -388.7 Million USD | 10.99% |
| 2020 FY | -388.7 Million USD | -201.43% |
| 2020 Q3 | -436.7 Million USD | -592.33% |
| 2020 Q2 | 88.7 Million USD | -71.63% |
| 2020 Q1 | 312.7 Million USD | -18.4% |
| 2019 Q1 | 387.8 Million USD | 57.14% |
| 2019 Q2 | 323.66 Million USD | -16.54% |
| 2019 Q3 | 311.43 Million USD | -3.78% |
| 2019 Q4 | 383.22 Million USD | 23.05% |
| 2019 FY | 383.22 Million USD | 55.29% |
| 2018 Q4 | 246.78 Million USD | 31.33% |
| 2018 Q1 | 198.89 Million USD | 73.1% |
| 2018 Q2 | 212.46 Million USD | 6.82% |
| 2018 Q3 | 187.91 Million USD | -11.55% |
| 2018 FY | 246.78 Million USD | 114.77% |
| 2017 Q1 | -64.08 Million USD | 23.03% |
| 2017 Q4 | 114.9 Million USD | 18.1% |
| 2017 Q3 | 97.29 Million USD | 90.09% |
| 2017 Q2 | 51.18 Million USD | 179.86% |
| 2017 FY | 114.9 Million USD | 238.0% |
| 2016 Q3 | -99.76 Million USD | -15.67% |
| 2016 Q4 | -83.26 Million USD | 16.53% |
| 2016 Q1 | -115.3 Million USD | -55.4% |
| 2016 FY | -83.26 Million USD | -12.23% |
| 2016 Q2 | -86.24 Million USD | 25.2% |
| 2015 Q2 | -132.07 Million USD | 22.43% |
| 2015 FY | -74.19 Million USD | -139.23% |
| 2015 Q3 | -66.37 Million USD | 49.74% |
| 2015 Q4 | -74.19 Million USD | -11.78% |
| 2015 Q1 | -170.26 Million USD | -448.98% |
| 2014 Q3 | -29.04 Million USD | 22.43% |
| 2014 Q2 | -37.44 Million USD | 64.52% |
| 2014 FY | -31.01 Million USD | 30.76% |
| 2014 Q1 | -105.53 Million USD | -135.62% |
| 2014 Q4 | -31.01 Million USD | -6.78% |
| 2013 Q4 | -44.78 Million USD | -28.38% |
| 2013 FY | -44.78 Million USD | 29.75% |
| 2013 Q3 | -34.88 Million USD | 21.27% |
| 2013 Q1 | -31.55 Million USD | 50.51% |
| 2013 Q2 | -44.31 Million USD | -40.43% |
| 2012 Q1 | -76.94 Million USD | -53.55% |
| 2012 Q2 | -42.01 Million USD | 45.39% |
| 2012 Q3 | -44.48 Million USD | -5.88% |
| 2012 Q4 | -63.75 Million USD | -43.31% |
| 2012 FY | -63.75 Million USD | -27.24% |
| 2011 FY | -50.1 Million USD | 7.3% |
| 2011 Q4 | -50.1 Million USD | -26.8% |
| 2011 Q3 | -39.51 Million USD | -109.77% |
| 2011 Q2 | -18.83 Million USD | 22.77% |
| 2011 Q1 | -24.39 Million USD | 54.87% |
| 2010 Q1 | -41.69 Million USD | -61.6% |
| 2010 FY | -54.05 Million USD | -109.51% |
| 2010 Q4 | -54.05 Million USD | 21.43% |
| 2010 Q3 | -68.79 Million USD | 19.61% |
| 2010 Q2 | -85.57 Million USD | -105.26% |
| 2009 Q4 | -25.79 Million USD | -43.01% |
| 2009 Q2 | -20.45 Million USD | 38.86% |
| 2009 FY | -25.79 Million USD | 62.32% |
| 2009 Q1 | -33.44 Million USD | 51.15% |
| 2009 Q3 | -18.04 Million USD | 11.79% |
| 2008 Q3 | -79.84 Million USD | 12.56% |
| 2008 FY | -68.46 Million USD | 30.26% |
| 2008 Q1 | -106.61 Million USD | -8.59% |
| 2008 Q2 | -91.31 Million USD | 14.35% |
| 2008 Q4 | -68.46 Million USD | 14.25% |
| 2007 Q4 | -98.17 Million USD | -44324.43% |
| 2007 FY | -98.17 Million USD | -259.1% |
| 2007 Q3 | -221 Thousand USD | 21.35% |
| 2007 Q2 | -281 Thousand USD | 98.92% |
| 2007 Q1 | -26.05 Million USD | 4.7% |
| 2006 Q2 | -29.71 Million USD | 31.75% |
| 2006 FY | -27.34 Million USD | -389.13% |
| 2006 Q4 | -27.34 Million USD | -31.64% |
| 2006 Q1 | -43.54 Million USD | -560.49% |
| 2006 Q3 | -20.76 Million USD | 30.11% |
| 2005 Q3 | -14.39 Million USD | -201.81% |
| 2005 FY | 9.45 Million USD | 85.45% |
| 2005 Q1 | 19.83 Million USD | 289.06% |
| 2005 Q2 | 14.13 Million USD | -28.75% |
| 2005 Q4 | 9.45 Million USD | 165.71% |
| 2004 Q1 | 9.12 Million USD | 113.14% |
| 2004 Q3 | -15.99 Million USD | -144.26% |
| 2004 Q2 | 36.14 Million USD | 296.28% |
| 2004 Q4 | 5.09 Million USD | 131.88% |
| 2004 FY | 5.09 Million USD | 107.35% |
| 2003 FY | -69.42 Million USD | -90.83% |
| 2003 Q3 | -101.29 Million USD | -714.97% |
| 2003 Q2 | -12.42 Million USD | 79.32% |
| 2003 Q1 | -60.1 Million USD | -65.23% |
| 2003 Q4 | -69.42 Million USD | 31.47% |
| 2002 FY | -36.37 Million USD | 77.01% |
| 2002 Q3 | -49.93 Million USD | -18.15% |
| 2002 Q4 | -36.37 Million USD | 27.15% |
| 2002 Q2 | -42.26 Million USD | 8.52% |
| 2002 Q1 | -46.19 Million USD | 70.8% |
| 2001 Q4 | -158.2 Million USD | -1826.93% |
| 2001 FY | -158.2 Million USD | -819.35% |
| 2001 Q1 | -23.79 Million USD | -38.28% |
| 2001 Q2 | -21.26 Million USD | 10.63% |
| 2001 Q3 | -8.21 Million USD | 61.4% |
| 2000 FY | -17.2 Million USD | 5.45% |
| 2000 Q1 | -9.11 Million USD | 49.92% |
| 2000 Q2 | 161 Thousand USD | 101.77% |
| 2000 Q3 | -8.1 Million USD | -5134.78% |
| 2000 Q4 | -17.2 Million USD | -112.29% |
| 1999 Q1 | -2.6 Million USD | 70.11% |
| 1999 Q2 | -9.6 Million USD | -269.23% |
| 1999 Q3 | -4.5 Million USD | 53.13% |
| 1999 Q4 | -18.2 Million USD | -304.44% |
| 1999 FY | -18.2 Million USD | -109.2% |
| 1998 Q2 | -8.9 Million USD | 31.01% |
| 1998 Q4 | -8.7 Million USD | 43.51% |
| 1998 Q1 | -12.9 Million USD | 9.15% |
| 1998 FY | -8.7 Million USD | 38.73% |
| 1998 Q3 | -15.4 Million USD | -73.03% |
| 1997 Q2 | -21.7 Million USD | -261.67% |
| 1997 Q4 | -14.2 Million USD | -1.43% |
| 1997 Q1 | -6 Million USD | 38.14% |
| 1997 FY | -14.2 Million USD | -46.39% |
| 1997 Q3 | -14 Million USD | 35.48% |
| 1996 Q4 | -9.7 Million USD | -64.41% |
| 1996 Q2 | -21.7 Million USD | -1086.36% |
| 1996 Q1 | 2.2 Million USD | 0.0% |
| 1996 FY | -9.7 Million USD | 0.0% |
| 1996 Q3 | -5.9 Million USD | 72.81% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | 303.522% |
| Dynavax Technologies Corporation | 106.63 Million USD | -66.268% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 628.828% |
| Perrigo Company plc | 3.32 Billion USD | 94.663% |
| Illumina, Inc. | 1.21 Billion USD | 85.395% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.339% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 255.679% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 97.847% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 98.621% |
| Heron Therapeutics, Inc. | 145.07 Million USD | -22.212% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 754.244% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -2366.954% |
| Waters Corporation | 1.96 Billion USD | 90.956% |
| Biogen Inc. | 6.28 Billion USD | 97.18% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 2597.183% |
| Evolus, Inc. | 63.7 Million USD | -178.301% |
| Adicet Bio, Inc. | -142 Million USD | 224.852% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 2066.504% |
| bluebird bio, Inc. | 108.57 Million USD | -63.303% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 61.347% |
| FibroGen, Inc. | 56.76 Million USD | -212.329% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 84.515% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -2444.461% |
| Homology Medicines, Inc. | 18.43 Million USD | -861.653% |
| Geron Corporation | 14.76 Million USD | -1101.138% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 88.816% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 10.484% |
| Myriad Genetics, Inc. | 88.1 Million USD | -101.249% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 426.784% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 259.153% |
| Zoetis Inc. | 4.76 Billion USD | 96.277% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 1860.5% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 91.549% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 53.188% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 101.854% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 1316.717% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 83.183% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | -456.061% |
| Verastem, Inc. | -37.27 Million USD | 575.616% |
| Nektar Therapeutics | 210.24 Million USD | 15.668% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 188.729% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 581.741% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 81.691% |
| OPKO Health, Inc. | 230.68 Million USD | 23.141% |
| Exelixis, Inc. | -73.05 Million USD | 342.71% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 230.945% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 217.399% |
| uniQure N.V. | -102.95 Million USD | 272.218% |
| Imunon, Inc. | -4.69 Million USD | 3872.924% |
| Blueprint Medicines Corporation | 702.83 Million USD | 74.774% |
| Insmed Incorporated | 721.62 Million USD | 75.43% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 87.16% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 667.96% |
| TG Therapeutics, Inc. | 17.86 Million USD | -892.61% |
| Incyte Corporation | -3.17 Billion USD | 105.584% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 76.848% |